新诺威现在的估值,已经走到必须要有所出的阶段:在创新药大反攻节点上,如果新诺威能释放出一个BD预期,市值突破将迎刃而解。资深分析师:摩 西编审:苏 叶5000万年度盈利,对应500亿估值、1000倍动态市盈率,这是A股Biotech新贵——新诺威履新“石药创新制药”身份后,首个完整财年的结算画面。但财报一出,盘中近8%的跌幅彰显了投资者的态度,且在次交易日,新诺威仍以超5%的跌幅收盘。其实...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.